Lipid-based nanocarriers for oral peptide delivery

Advanced Drug Delivery Reviews

Volumn 106, Issue , 2016, Pages 337-354

  Niu, Zhigao ^a   Conejos Sánchez, Inmaculada ^a   Griffin, Brendan T ^b   O'Driscoll, Caitriona M ^b   Alonso, María J ^a  

^a University of Santiago de Compostela ^*  (Spain)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Lipid formulation; Liposome; Nano microemulsion; Nanocapsule; Oral delivery; Peptide drug; Self emulsifying system; Solid lipid nanoparticle

Indexed keywords

COMMERCIAL VEHICLES; EMULSIFICATION; LIPOSOMES; NANOCAPSULES; PARTICLE SIZE; PARTICLE SIZE ANALYSIS; PROTEINS;

NANO/MICROEMULSION; ORAL DELIVERY; PEPTIDE DRUGS; SELF-EMULSIFYING; SOLID LIPID NANOPARTICLE (SLN);

PEPTIDES;

APROTININ; BACITRACIN; BOVINE SERUM ALBUMIN; CAMOSTAT MESILATE; CYCLOSPORIN A; EPIDERMAL GROWTH FACTOR; ERYTHROPOIETIN; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCOCHOLATE SODIUM; GONADORELIN; INSULIN; INSULIN GLARGINE; LEUPRORELIN; LEVOTHYROXINE; LIPID; LIPOSOME; LYSOZYME; NANOCAPSULE; NANOCARRIER; OCTREOTIDE; OMEGA 3 FATTY ACID; OVALBUMIN; PARATHYROID HORMONE[1-34]; PEPTIDE; SALCATONIN; SOLID LIPID NANOPARTICLE; TAURODEOXYCHOLIC ACID; THYMOPENTIN; UNINDEXED DRUG; VASCULOTROPIN; DRUG CARRIER; NANOMATERIAL;

ANTIDIABETIC ACTIVITY; CONTROLLED DRUG RELEASE; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG TRANSPORT; HUMAN; INTESTINE EPITHELIUM; INTESTINE MUCOSA PERMEABILITY; INTRACOLONIC DRUG ADMINISTRATION; LIPOSOMAL DELIVERY; MICROEMULSION; NANOEMULSION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SELF EMULSIFYING DRUG DELIVERY SYSTEM; SELF MICROEMULSIFYING DRUG DELIVERY SYSTEM; SELF NANOEMULSIFYING DRUG DELIVERY SYSTEM; SUSTAINED DRUG RELEASE; TIGHT JUNCTION; ZETA POTENTIAL; CHEMISTRY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; DRUG CARRIERS; HUMANS; LIPIDS; NANOSTRUCTURES; PEPTIDES;

EID: 84963954616     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.04.001     Document Type: Review

References (245)

1. [1] Global Markets and Manufacturing Technologies for Protein Drugs. http://www.bccresearch.com/market-research/biotechnology/protein-drugs-therapeutics-bio021d.html, 2013.
2. [2] Protein and peptide-Based Therapeutics: Trends in Drug Discovery, http://www.bionity.com/en/studies/11884/protein-and-peptide-based-therapeutics-trends-in-drug-discovery-and-development.html.
3. [3] Chen, M.L., Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective. Adv. Drug Deliv. Rev. 60:6 (2008), 768–777.
4. [4] Souto, E.B., Doktorovova, S., Boonme, P., Lipid-based colloidal systems (nanoparticles, microemulsions) for drug delivery to the skin: materials and end-product formulations. J. Drug Deliv. Sci. Technol. 21:1 (2011), 43–54.
5. [5] Pouton, C.W., Porter, C.J., Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv. Drug Deliv. Rev. 60:6 (2008), 625–637.
6. [6] Hauss, D.J., Oral lipid-based formulations. Adv. Drug Deliv. Rev. 59:7 (2007), 667–676.
7. [7] Thomas, N., Rades, T., Müllertz, A., Recent developments in oral lipid-based drug delivery. J. Drug Deliv. Sci. Technol. 23:4 (2013), 375–382.
8. [8] Liu, D., Kobayashi, T., Russo, S., Li, F., Plevy, S.E., Gambling, T.M., et al. In vitro and in vivo evaluation of a water-in-oil microemulsion system for enhanced peptide intestinal delivery. AAPS J. 15:1 (2013), 288–298.
9. [9] Čilek, A., Čelebi, N., Tirnaksiz, F., Lecithin-based microemulsion of a peptide for oral administration: preparation, characterization, and physical stability of the formulation. Drug Deliv. 13:1 (2006), 19–24.
10. [10] E., H., Chapter 6—plant glycolipids: structure, isolation and analysis. WW, C., (eds.) Advances in Lipid Methodology, 2012, Woodhead Publishing, 211–332.
11. [11] Pouton, C.W., Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and ‘self-microemulsifying’ drug delivery systems. Eur. J. Pharm. Sci. 11:Suppl. 2 (2000), S93–S98.
12. [12] Renukuntla, J., Vadlapudi, A.D., Patel, A., Boddu, S.H., Mitra, A.K., Approaches for enhancing oral bioavailability of peptides and proteins. Int. J. Pharm. 447:1-2 (2013), 75–93.
13. [13] Tuvia, S., Atsmon, J., Teichman, S.L., Katz, S., Salama, P., Pelled, D., et al. Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J. Clin. Endocrinol. Metab. 97:7 (2012), 2362–2369.
14. [14] Melmed, S., Popovic, V., Bidlingmaier, M., Mercado, M., van der Lely, A.J., Biermasz, N., et al. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J. Clin. Endocrinol. Metab. 100:4 (2015), 1699–1708.
15. [15] Walsh, E.G., Adamczyk, B.E., Chalasani, K.B., Maher, S., O'Toole, E.B., Fox, J.S., et al. Oral delivery of macromolecules: rationale underpinning gastrointestinal permeation enhancement technology (GIPET). Ther. Deliv. 2:12 (2011), 1595–1610.
16. [16] Pharma, M., Novo Nordisk A/S successfully completes single dose phase 1 trial of a novel oral insulin (NN11956) and oral GLP-1 analogue (NN9928) using Merrion Pharmaceuticals GIPET technology. http://www.merrionpharma.com/content/investors/archive/2014/290914.asp (accessed 09 Sep 2015), 2014.
17. [17] Clinicaltrials.gov. Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects with Type 2 Diabetes Currently Treated with Oral Antidiabetic Therapy. https://clinicaltrials.gov/ct2/show/NCT02470039?term=GIPET&rank=5 (last accessed 24 Sep 2015), 2015.
18. [18] Swenson, E.S., Milsen, W.B., Curtalo, W.J., Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility. Pharm. Res. 11:8 (1994), 1132–1142.
19. [19] Aungst, B.J., Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism. J. Pharm. Sci. 82:10 (1993), 979–987.
20. [20] Cornaire, G., Woodley, J., Hermann, P., Cloarec, A., Arellano, C., Houin, G., Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int. J. Pharm. 278:1 (2004), 119–131.
21. [21] Meaney, C.M., CM, O.'.D., A comparison of the permeation enhancement potential of simple bile salt and mixed bile salt: fatty acid micellar systems using the Caco-2 cell culture model. Int. J. Pharm. 207:1-2 (2000), 21–30.
22. [22] Griffin, B.T., O'Driscoll, C.M., Opportunities and challenges for oral delivery of hydrophobic versus hydrophilic peptide and protein-like drugs using lipid-based technologies. Ther. Deliv. 2:12 (2011), 1633–1653.
23. [23] Mahato, R.I., Narang, A.S., Thoma, L., Miller, D.D., Emerging trends in oral delivery of peptide and protein drugs. Crit. Rev. Ther. Drug Carrier Syst. 20:2-3 (2003), 153–214.
24. [24] Anderberg, E.K., Lindmark, T., Artursson, P., Sodium caprate elicits dilatations in human intestinal tight junctions and enhances drug absorption by the paracellular route. Pharm. Res. 10:6 (1993), 857–864.
25. [25] Aungst, B.J., Intestinal permeation enhancers. J. Pharm. Sci. 89:4 (2000), 429–442.
26. [26] Swenson, E.S., Curtalo, W.J., Intestinal permeability enhancement for proteins, peptides and other polar drugs: mechanisms and potential toxicity. Adv. Drug Deliv. Rev. 8 (1992), 39–92.
27. [27] Lane, M.E., O'Driscoll, C.M., Corrigan, O.I., Quantitative estimation of the effects of bile salt surfactant systems on insulin stability and permeability in the rat intestine using a mass balance model. J. Pharm. Pharmacol. 57:2 (2005), 169–175.
28. [28] Morley, P., Delivery of parathyroid hormone for the treatment of osteoporosis. Expert Opin. Drug Deliv. 2:6 (2005), 993–1002.
29. [29] Eldor, R., Arbit, E., Corcos, A., Kidron, M., Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study. PLoS One, 8(4), 2013, e59524.
30. [30] Maher, S., Ryan, B., Duffy, A., Brayden, D.J., Formulation strategies to improve oral peptide delivery. Pharm. Pat. Anal. 3:3 (2014), 313–336.
31. [31] Sha, X., Yan, G., Wu, Y., Li, J., Fang, X., Effect of self-microemulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells. Eur. J. Pharm. Sci. 24:5 (2005), 477–486.
32. [32] Anderberg, E.K., Artursson, P., Epithelial transport of drugs in cell culture. VIII: effects of sodium dodecyl sulfate on cell membrane and tight junction permeability in human intestinal epithelial (Caco-2) cells. J. Pharm. Sci. 82:4 (1993), 392–398.
33. [33] Hayashi, M., Sakai, T., Hasegawa, Y., Nishikawahara, T., Tomioka, H., Iida, A., et al. Physiological mechanism for enhancement of paracellular drug transport. J. Control. Release 62:1-2 (1999), 141–148.
34. [34] Maher, S., Leonard, T.W., Jacobsen, J., Brayden, D.J., Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic. Adv. Drug Deliv. Rev. 61:15 (2009), 1427–1449.
35. [35] Leonard, T.W., Lynch, J., McKenna, M.J., Brayden, D.J., Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPET. Expert Opin. Drug Deliv. 3:5 (2006), 685–692.
36. [36] Leone-Bay, A., Ho, K.K., Agarwal, R., Baughman, R.A., Chaudhary, K., DeMorin, F., et al. 4-[4-[(2-Hydroxybenzoyl)amino]phenyl]butyric acid as a novel oral delivery agent for recombinant human growth hormone. J. Med. Chem. 39:13 (1996), 2571–2578.
37. [37] Milstein, S.J., Leipold, H., Sarubbi, D., Leone-Bay, A., Mlynek, G.M., Robinson, J.R., et al. Partially unfolded proteins efficiently penetrate cell membranes—implications for oral drug delivery. J. Control. Release 53:1-3 (1998), 259–267.
38. [38] Malkov, D., Angelo, R., Wang, H.Z., Flanders, E., Tang, H., Gomez-Orellana, I., Oral delivery of insulin with the eligen technology: mechanistic studies. Curr. Drug Deliv. 2:2 (2005), 191–197.
39. [39] Dressman, J., Lennerna, H., Reppas, C., Oral drug absorption: prediction and assessment. Drugs and the pharmaceutical sciences, second ed., 2010, Informa Healthcare, New York, London.
40. [40] Mashkevich, B.O., Drug delivery research advances. 2007, Nova Science, Lancaster, Gazelle Drake Academic, Hauppauge, N.Y.
41. [41] Ingels, F., Beck, B., Oth, M., Augustijns, P., Effect of simulated intestinal fluid on drug permeability estimation across Caco-2 monolayers. Int. J. Pharm. 274:1-2 (2004), 221–232.
42. [42] Yamamoto, A., Taniguchi, T., Rikyuu, K., Tsuji, T., Fujita, T., Murakami, M., et al. Effects of various protease inhibitors on the intestinal-absorption and degradation of insulin in rats. Pharm. Res. 11:10 (1994), 1496–1500.
43. [43] Martins, S., Sarmento, B., Ferreira, D.C., Souto, E.B., Lipid-based colloidal carriers for peptide and protein delivery–liposomes versus lipid nanoparticles. Int. J. Nanomedicine 2:4 (2007), 595–607.
44. [44] Lawless, E., Griffin, B.T., O'Mahony, A., O'Driscoll, C.M., Exploring the impact of drug properties on the extent of intestinal lymphatic transport—in vitro and in vivo studies. Pharm. Res. 32:5 (2015), 1817–1829.
45. [45] Muranishi, S., Delivery system design for improvement of intestinal absorption of peptide drugs. Yakugaku Zasshi 117:7 (1997), 394–414.
46. [46] Trevaskis, N.L., Kaminskas, L.M., Porter, C.J., From sewer to saviour—targeting the lymphatic system to promote drug exposure and activity. Nat. Rev. Drug Discov. 14:11 (2015), 781–803.
47. [47] Attili-Qadri, S., Karra, N., Nemirovski, A., Schwob, O., Talmon, Y., Nassar, T., et al. Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorption. Proc. Natl. Acad. Sci. U. S. A. 110:43 (2013), 17498–17503.
48. [48] Zhang, N., Ping, Q., Huang, G., Xu, W., Cheng, Y., Han, X., Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int. J. Pharm. 327:1-2 (2006), 153–159.
49. [49] Zhang, P., Xu, Y., Zhu, X., Huang, Y., Goblet cell targeting nanoparticle containing drug-loaded micelle cores for oral delivery of insulin. Int. J. Pharm. 496:2 (2015), 993–1005.
50. [50] Ritschel, W.A., Microemulsions for improved peptide absorption from the gastrointestinal tract. Methods Find. Exp. Clin. Pharmacol. 13:3 (1991), 205–220.
51. [51] Rizwan, S.B., Boyd, B.J., Rades, T., Hook, S., Bicontinuous cubic liquid crystals as sustained delivery systems for peptides and proteins. Expert Opin. Drug Deliv. 7:10 (2010), 1133–1144.
52. [52] Dong, A.W., Fong, C., Waddington, L.J., Hill, A.J., Boyd, B.J., Drummond, C.J., Packing and mobility of hydrocarbon chains in phospholipid lyotropic liquid crystalline lamellar phases and liposomes: characterisation by positron annihilation lifetime spectroscopy (PALS). Phys. Chem. Chem. Phys. 17:1 (2015), 276–286.
53. [53] Sadhale, Y., Shah, J.C., Biological activity of insulin in GMO gels and the effect of agitation. Int. J. Pharm. 191:1 (1999), 65–74.
54. [54] Sadhale, Y., Shah, J.C., Stabilization of insulin against agitation-induced aggregation by the GMO cubic phase gel. Int. J. Pharm. 191:1 (1999), 51–64.
55. [55] Rizwan, S.B., Hanley, T., Boyd, B.J., Rades, T., Hook, S., Liquid crystalline systems of phytantriol and glyceryl monooleate containing a hydrophilic protein: characterisation, swelling and release kinetics. J. Pharm. Sci. 98:11 (2009), 4191–4204.
56. [56] Boyd, B.J., Khoo, S.M., Whittaker, D.V., Davey, G., Porter, C.J., A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats. Int. J. Pharm. 340:1-2 (2007), 52–60.
57. [57] Müller, R.H., Mäder, K., Gohla, S., Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur. J. Pharm. Biopharm. 50:1 (2000), 161–177.
58. [58] Gasco MR. Method for producing solid lipid microspheres having a narrow size distribution. US-Patent 5250236; 1993.
59. [59] Lucks, J.S., Müller, R.H., Medication Vehicles Made of Solid Lipid Particles (Solid Lipid Nanospheres-SLN). EP19920919477, WO/1993/005768. 1993.
60. [60] Jannin, V., Dellera, E., Chevrier, S., Chavant, Y., Voutsinas, C., Bonferoni, C., Demarne, F., In vitro lipolysis tests on lipid nanoparticles: comparison between lipase/co-lipase and pancreatic extract. Drug Dev. Ind. Pharm. 41:10 (2015), 1582–1588.
61. [61] Almeida, A.J., Souto, E., Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev. 59:6 (2007), 478–490.
62. [62] Ramakrishna, B.S., Mathan, M., Mathan, V.I., Alteration of colonic absorption by long-chain unsaturated fatty acids. Influence of hydroxylation and degree of unsaturation. Scand. J. Gastroenterol. 29:1 (1994), 54–58.
63. [63] Schütz, C.A., Staedler, D., Crosbie-Staunton, K., Movia, D., Chapuis Bernasconi, C., Kenzaoui, B.H., et al. Differential stress reaction of human colon cells to oleic-acid-stabilized and unstabilized ultrasmall iron oxide nanoparticles. Int. J. Nanomedicine 9 (2014), 3481–3498.
64. [64] Müller, R.H., Shegokar, R., Keck, C.M., 20 years of lipid nanoparticles (SLN & NLC): present state of development & industrial applications. Curr. Drug Discov. Technol. 8:3 (2011), 207–227.
65. [65] Harde, H., Das, M., Jain, S., Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. Expert Opin. Drug Deliv. 8:11 (2011), 1407–1424.
66. [66] Trotta, M., Cavalli, R., Carlotti, M.E., Battaglia, L., Debernardi, F., Solid lipid micro-particles carrying insulin formed by solvent-in-water emulsion-diffusion technique. Int. J. Pharm. 288:2 (2005), 281–288.
67. [67] Trotta, M., Debernardi, F., Caputo, O., Preparation of solid lipid nanoparticles by a solvent emulsification–diffusion technique. Int. J. Pharm. 257:1-2 (2003), 153–160.
68. [68] Battaglia, L., Trotta, M., Gallarate, M., Carlotti, M.E., Zara, G.P., Bargoni, A., Solid lipid nanoparticles formed by solvent-in-water emulsion-diffusion technique: development and influence on insulin stability. J. Microencapsul. 24:7 (2007), 660–672.
69. [69] Sjöström, B., Bergenståhl, B., Preparation of submicron drug particles in lecithin-stabilized o/w emulsions I. Model studies of the precipitation of cholesteryl acetate. Int. J. Pharm. 88:1–3 (1992), 53–62.
70. [70] Garcia-Fuentes, M., Torres, D., Alonso, M.J., Design of lipid nanoparticles for oral delivery of hydrophilic macromolecules., 27(2-3), 2003, 159–168.
71. [71] Garcia-Fuentes, M., Torres, D., Alonso, M.J., New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin. Int. J. Pharm. 296:1-2 (2005), 122–132.
72. [72] Chen, C., Fan, T., Jin, Y., Zhou, Z., Yang, Y., Zhu, X., et al. Orally delivered salmon calcitonin-loaded solid lipid nanoparticles prepared by micelle–double emulsion method via the combined use of different solid lipids. Nanomedicine 8:7 (2012), 1085–1100.
73. [73] Liu, J., Gong, T., Wang, C., Zhong, Z., Zhang, Z., Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: preparation and characterization. Int. J. Pharm. 340:1-2 (2007), 153–162.
74. [74] Yuan, H., Jiang, S.P., Du, Y.Z., Miao, J., Zhang, X.G., Hu, F.Q., Strategic approaches for improving entrapment of hydrophilic peptide drugs by lipid nanoparticles. Colloids Surf. B: Biointerfaces 70:2 (2009), 248–253.
75. [75] Kashanian, S., Rostami, E., PEG-stearate coated solid lipid nanoparticles as levothyroxine carriers for oral administration. J. Nanoparticle Res., 16(3), 2014.
76. [76] Gallarate, M., Trotta, M., Battaglia, L., Chirio, D., Preparation of solid lipid nanoparticles from w/o/w emulsions: preliminary studies on insulin encapsulation. J. Microencapsul. 26:5 (2009), 394–402.
77. [77] Sarmento, B., Martins, S., Ferreira, D., Souto, E.B., Oral insulin delivery by means of solid lipid nanoparticles. Int. J. Nanomedicine 2:4 (2007), 743–749.
78. [78] Zhang, Z.-H., Zhang, Y.-L., Zhou, J.-P., Lv, H.-X., Solid lipid nanoparticles modified with stearic acid-octaarginine for oral administration of insulin. Int. J. Nanomedicine 7 (2012), 3333–3339.
79. [79] Wang, S.L., Xie, S.Y., Zhu, L.Y., Wang, F.H., Zhou, W.Z., Effects of poly (lactic-co-glycolic acid) as a co-emulsifier on the preparation and hypoglycaemic activity of insulin-loaded solid lipid nanoparticles. IET Nanobiotechnol. 3:4 (2009), 103–108.
80. [80] Fan, T., Chen, C., Guo, H., Xu, J., Zhang, J., Zhu, X., et al. Design and evaluation of solid lipid nanoparticles modified with peptide ligand for oral delivery of protein drugs. Eur. J. Pharm. Biopharm. 88:2 (2014), 518–528.
81. [81] Prego, C., Fabre, M., Torres, D., Alonso, M.J., Efficacy and mechanism of action of chitosan nanocapsules for oral peptide delivery. Pharm. Res. 23:3 (2006), 549–556.
82. [82] Garcia-Fuentes, M., Prego, C., Torres, D., Alonso, M.J., A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery. Eur. J. Pharm. Sci. 25:1 (2005), 133–143.
83. [83] Prego, C., García, M., Torres, D., Alonso, M.J., Transmucosal macromolecular drug delivery. J. Control. Release 101:1–3 (2005), 151–162.
84. [84] Hu, F.Q., Hong, Y., Yuan, H., Preparation and characterization of solid lipid nanoparticles containing peptide. Int. J. Pharm. 273:1-2 (2004), 29–35.
85. [85] Yang, R., Gao, R., Li, F., He, H., Tang, X., The influence of lipid characteristics on the formation, in vitro release, and in vivo absorption of protein-loaded SLN prepared by the double emulsion process. Drug Dev. Ind. Pharm. 37:2 (2011), 139–148.
86. [86] Yang, R., Gao, R.-C., Cai, C.-F., Xu, H., Li, F., He, H.-B., et al. Preparation of gel-core-solid lipid nanoparticle: a novel way to improve the encapsulation of protein and peptide. Chem. Pharm. Bull. 58:9 (2010), 1195–1202.
87. [87] Christophersen, P.C., Zhang, L., Yang, M., Nielsen, H.M., Mullertz, A., Mu, H., Solid lipid particles for oral delivery of peptide and protein drugs I—elucidating the release mechanism of lysozyme during lipolysis. Eur. J. Pharm. Biopharm. 85:3 Pt A (2013), 473–480.
88. [88] Oh, K.S., Han, S.K., Lee, H.S., Koo, H.M., Kim, R.S., Lee, K.E., et al. Core/shell nanoparticles with lecithin lipid cores for protein delivery. Biomacromolecules 7:8 (2006), 2362–2367.
89. [89] Schulman, J.H., Stoeckenius, W., Prince, L.M., Mechanism of formation and structure of micro emulsions by electron microscopy. J. Phys. Chem. 63:10 (1959), 1677–1680.
90. [90] Hoar, T.P., Schulman, J.H., Transparent water-in-oil dispersions: the oleopathic hydro-micelle. Nature 152 (1943), 102–103.
91. [91] Plapied, L., Duhem, N., des Rieux, A., Préat, V., Fate of polymeric nanocarriers for oral drug delivery. Curr. Opin. Colloid Interface Sci. 16:3 (2011), 228–237.
92. [92] Anton, N., Benoit, J.P., Saulnier, P., Design and production of nanoparticles formulated from nano-emulsion templates-a review. J. Control. Release 128:3 (2008), 185–199.
93. [93] McClements, D.J., Nanoemulsions versus microemulsions: terminology, differences, and similarities. Soft Matter 8:6 (2012), 1719–1729.
94. [94] Abismail, B., Canselier, J.P., Wilhelm, A.M., Delmas, H., Gourdon, C., Emulsification by ultrasound: drop size distribution and stability. Ultrason. Sonochem. 6:1-2 (1999), 75–83.
95. [95] Asua, J.M., Challenges for industrialization of miniemulsion polymerization. Prog. Polym. Sci. 39:10 (2014), 1797–1826.
96. [96] McClements, D.J., Nanoemulsion-based oral delivery systems for lipophilic bioactive components: nutraceuticals and pharmaceuticals. Ther. Deliv. 4:7 (2013), 841–857.
97. [97] Leroux, J.C., Allémann, E., Doelker, E., Gurny, R., New approach for the preparation of nanoparticles by an emulsification-diffusion method. Eur. J. Pharm. Biopharm. 41:1 (1995), 14–18.
98. [98] Shlomo, M., Liat, S., A method for the preparation of nanoparticles from nanoemulsions. WO2005102507 A1. 2005.
99. [99] Shinoda, K., Saito, H., The Stability of o/w type emulsions as functions of temperature and the HLB of emulsifiers: the emulsification by PIT-method. J. Colloid Interface Sci. 30:2 (1969), 258–263.
100. [100] Shinoda, K., Saito, H., The effect of temperature on the phase equilibria and the types of dispersions of the ternary system composed of water, cyclohexane, and nonionic surfactant. J. Colloid Interface Sci. 26:1 (1968), 70–74.
101. [101] Gershanik, T., Benita, S., Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur. J. Pharm. Biopharm. 50:1 (2000), 179–188.
102. [102] Griffin, B., O'Driscoll, C., Opportunities and challenges for oral delivery of hydrophobic versus hydrophilic peptide and protein-like drugs using lipid-based technologies. Ther. Deliv. 2:12 (2011), 1633–1653.
103. [103] Sharma, G., Wilson, K., van der Walle, C.F., Sattar, N., Petrie, J.R., Ravi Kumar, M.N., Microemulsions for oral delivery of insulin: design, development and evaluation in streptozotocin induced diabetic rats. Eur. J. Pharm. Biopharm. 76:2 (2010), 159–169.
104. [104] Elsayed, A., Remawi, M.A., Qinna, N., Farouk, A., Badwan, A., Formulation and characterization of an oily-based system for oral delivery of insulin. Eur. J. Pharm. Biopharm. 73:2 (2009), 269–279.
105. [105] Toorisaka, E., Hashida, M., Kamiya, N., Ono, H., Kokazu, Y., Goto, M., An enteric-coated dry emulsion formulation for oral insulin delivery. J. Control. Release 107:1 (2005), 91–96.
106. [106] Toorisaka, E., Hypoglycemic effect of surfactant-coated insulin solubilized in a novel solid-in-oil-in-water (s/o/w) emulsion. Int. J. Pharm. 252:1-2 (2003), 271–274.
107. [107] Cunha, A.S., Grossior, J.L., Puisieux, F., Seiller, M., Insulin in w/o/w multiple emulsions: preparation, characterization and determination of stability towards proteases in vitro. J. Microencapsul. 14:3 (1997), 311–319.
108. [108] Suzuki, A., Morishita, M., Kajita, M., Takayama, K., Isowa, K., Chiba, Y., et al. Enhanced colonic and rectal absorption of insulin using a multiple emulsion containing eicosapentaenoic acid and docosahexaenoic acid. J. Pharm. Sci. 87:10 (1998), 1196–1202.
109. [109] Morishita, M., Matsuzawa, A., Takayama, K., Isowa, K., Nagai, T., Improving insulin enteral absorption using water-in-oil-in-water emulsion. Int. J. Pharm. 172:1–2 (1998), 189–198.
110. [110] Onuki, Y., Morishita, M., Takayama, K., Formulation optimization of water-in-oil-water multiple emulsion for intestinal insulin delivery. J. Control. Release 97:1 (2004), 91–99.
111. [111] Mesiha, M., Plakogiannis, F., Vejosoth, S., Enhanced oral absorption of insulin from desolvated fatty acid-sodium glycocholate emulsions. Int. J. Pharm. 111:3 (1994), 213–216.
112. [112] Trenktrog, T., Müller, B.W., Preparation and characterization of a peptide containing w/o emulsion. Int. J. Pharm. 123:2 (1995), 199–207.
113. [113] Dogru, S.T., Çalis, S., Öner, F., Oral multiple w/o/w emulsion formulation of a peptide salmon calcitonin: in vitro–in vivo evaluation. J. Clin. Pharm. Ther. 25:6 (2000), 435–443.
114. [114] Sun, H., Liu, K., Liu, W., Wang, W., Guo, C., Tang, B., et al. Development and characterization of a novel nanoemulsion drug-delivery system for potential application in oral delivery of protein drugs. Int. J. Nanomedicine 7 (2012), 5529–5543.
115. [115] Cheng, M.B., Wang, J.C., Li, Y.H., Liu, X.Y., Zhang, X., Chen, D.W., et al. Characterization of water-in-oil microemulsion for oral delivery of earthworm fibrinolytic enzyme. J. Control. Release 129:1 (2008), 41–48.
116. [116] Constantinides, P., Scalart, J.-P., Lancaster, C., Marcello, J., Marks, G., Ellens, H., et al. Formulation and intestinal absorption enhancement evaluation of water-in-oil microemulsions incorporating medium-chain glycerides. Pharm. Res. 11:10 (1994), 1385–1390.
117. [117] Shah, R.B., Ahsan, F., Khan, M.A., Oral delivery of proteins: progress and prognostication. Crit. Rev. Ther. Drug Carrier Syst. 19:2 (2002), 135–169.
118. [118] Park, K., Kwon, I.C., Park, K., Oral protein delivery: current status and future prospect. React. Funct. Polym. 71:3 (2011), 280–287.
119. [119] Alonso, M.J., Csaba, N.S., Nanostructured Biomaterials for Overcoming Biological Barriers: Royal Society of Chemistry. 2012.
120. [120] Anton, N., Vandamme, T.F., Nano-emulsions and micro-emulsions: clarifications of the critical differences. Pharm. Res. 28:5 (2011), 978–985.
121. [121] Strickley, R.G., Currently marketed oral lipid based dosage forms: drug products and excipeints. Hauss, D.J., (eds.) Oral Lipid based formulations Drugs and the Pharmaceutical Sciences, Informa healthcare, 2007, 1–32.
122. [122] Griffin, B.T., O'Driscoll, C.M., Opportunities and challenges for oral delivery of hydrophobic versus hydrophilic peptide and protein-like drugs using lipid-based technologies. Ther. Deliv. 2:12 (2011), 1633–1653.
123. [123] Toorisaka, E., Ono, H., Arimori, K., Kamiya, N., Goto, M., Hypoglycemic effect of surfactant-coated insulin solubilized in a novel solid-in-oil-in-water (s/o/w) emulsion. Int. J. Pharm. 252:1-2 (2003), 271–274.
124. [124] Fan, Y., Li, X., Zhou, Y., Fan, C., Wang, X., Huang, Y., et al. Improved intestinal delivery of salmon calcitonin by water-in-oil microemulsions. Int. J. Pharm. 416:1 (2011), 323–330.
125. [125] Bakala-N'Goma, J.C., Williams, H.D., Sassene, P., Kleberg, K., Calderone, M., Jannin, V., et al. Toward the establishment of standardized in vitro tests for lipid-based formulations. 5. Lipolysis of representative formulations by gastric lipase. Pharm. Res. 32:4 (2015), 1279–1287.
126. [126] Williams, H., Anby, M.U., Sassene, P., Kleberg, K., Bakala-N'Goma, J.C., Calderone, M., et al. Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug saturation level (dose) on the performance of Type I, II, IIIA, IIIB and IV formulations during in vitro digestion. Mol. Pharm. 9:11 (2012), 3286–3300.
127. [127] Mueller, E.A., Kovarik, J.M., van Bree, J.B., Tetzloff, W., Grevel, J., Kutz, K., Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm. Res. 11:2 (1994), 301–304.
128. [128] Heurtault, B., Saulnier, P., Pech, B., Proust, J.-E., Benoit, J.-P., A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm. Res. 19:6 (2002), 875–880.
129. [129] Groo, A.-C., Saulnier, P., Gimel, J.-C., Gravier, J., Ailhas, C., Benoit, J.P., et al. Fate of paclitaxel lipid nanocapsules in intestinal mucus in view of their oral delivery. Int. J. Nanomedicine 8 (2013), 4291–4302.
130. [130] Damgé, C., Michel, C., Aprahamian, M., Couvreur, P., New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes 37:2 (1988), 246–251.
131. [131] Lambert, G., Fattal, E., Pinto-Alphandary, H., Gulik, A., Couvreur, P., Polyisobutylcyanoacrylate nanocapsules containing an aqueous core for the delivery of oligonucleotides. Int. J. Pharm. 214:1–2 (2001), 13–16.
132. [132] Hillaireau, H., Le Doan, T., Besnard, M., Chacun, H., Janin, J., Couvreur, P., Encapsulation of antiviral nucleotide analogues azidothymidine-triphosphate and cidofovir in poly(iso-butylcyanoacrylate) nanocapsules. Int. J. Pharm. 324:1 (2006), 37–42.
133. [133] Quintanar-Guerrero, D., Allémann, E., Doelker, E., Fessi, H., A mechanistic study of the formation of polymer nanoparticles by the emulsification-diffusion technique. Colloid Polym. Sci. 275:7 (1997), 640–647.
134. [134] Calvo., P., Remufifin-Ldpez, C., Vila-Jato, J.L., Alonso, M.J., Development of positively charged colloidal drug carriers: chitosan-coated polyester nanocapsules and submicron-emulsions. Colloid Polym. Sci. 275 (1997), 46–53.
135. [135] Prego, C., Torres, D., Fernandez-Megia, E., Novoa-Carballal, R., Quinoa, E., Alonso, M.J., Chitosan-PEG nanocapsules as new carriers for oral peptide delivery. Effect of chitosan pegylation degree. J. Control. Release 111:3 (2006), 299–308.
136. [136] Oyarzun-Ampuero, F.A., Rivera-Rodríguez, G.R., Alonso, M.J., Torres, D., Hyaluronan nanocapsules as a new vehicle for intracellular drug delivery. Eur. J. Pharm. Sci. 49:4 (2013), 483–490.
137. [137] Ma, J., Feng, P., Ye, C., Wang, Y., Fan, Y., An improved interfacial coacervation technique to fabricate biodegradable nanocapsules of an aqueous peptide solution from polylactide and its block copolymers with poly(ethylene glycol). Colloid Polym. Sci. 279:4 (2001), 387–392.
138. [138] Sukhorukov, G.B., Donath, E., Lichtenfeld, H., Knippel, E., Knippel, M., Budde, A., et al. Layer-by-layer self assembly of polyelectrolytes on colloidal particles. Colloids Surf. A Physicochem. Eng. Asp. 137:1–3 (1998), 253–266.
139. [139] Prego, C., Torres, D., Alonso, M.J., Chitosan nanocapsules as carriers for oral peptide delivery: effect of chitosan molecular weight and type of salt on the in vitro behaviour and in vivo effectiveness. J. Nanosci. Nanotechnol. 6:9 (2006), 2921–2928.
140. [140] Lenherr, G., Csaba, N., Thwala, L., Niu, Z., Alonso, M.J., Nanocapsular formulation of active pharmaceutical ingredients. WO2015189387 A1. 2015.
141. [141] Li, X., Qi, J., Xie, Y., Zhang, X., Hu, S., Xu, Y., et al. Nanoemulsions coated with alginate/chitosan as oral insulin delivery systems: preparation, characterization, and hypoglycemic effect in rats. Int. J. Nanomedicine 8 (2013), 23–32.
142. [142] Zhu, Y., Zhang, G., Yang, H., Hong, X., Influence of surfactants on the parameters of polylactide nanocapsules containing insulin. J. Surfactant Deterg. 8:4 (2005), 353–358.
143. [143] Baluom, M., Friedman, D.I., Rubinstein, A., Absorption enhancement of calcitonin in the rat intestine by carbopol-containing submicron emulsions. Int. J. Pharm. 154:2 (1997), 235–243.
144. [144] Anton, N., Saulnier, P., Gaillard, C., Porcher, E., Vrignaud, S., Benoit, J.P., Aqueous-core lipid nanocapsules for encapsulating fragile hydrophilic and/or lipophilic molecules. Langmuir 25:19 (2009), 11413–11419.
145. [145] Cournarie, F., Chéron, M., Besnard, M., Vauthier, C., Evidence for restrictive parameters in formulation of insulin-loaded nanocapsules. Eur. J. Pharm. Biopharm. 57:2 (2004), 171–179.
146. [146] Calvo, P., Remuñán-López, C., Vila-Jato, J.L., Alonso, M.J., Development of positively charged colloidal drug carriers: chitosan-coated polyester nanocapsules and submicron-emulsions. Colloid Polym. Sci. 275:1 (1997), 46–53.
147. [147] Vrignaud, S., Benoit, J.P., Saulnier, P., Strategies for the nanoencapsulation of hydrophilic molecules in polymer-based nanoparticles. Biomaterials 32:33 (2011), 8593–8604.
148. [148] Li, S., He, Y., Li, C., Liu, X., In vitro release of protein from poly(butylcyanoacrylate) nanocapsules with an aqueous core. Colloid Polym. Sci. 283:5 (2004), 480–485.
149. [149] Watnasirichaikul, S., Rades, T., Tucker, I.G., Davies, N.M., In-vitro release and oral bioactivity of insulin in diabetic rats using nanocapsules dispersed in biocompatible microemulsion. J. Pharm. Pharmacol. 54:4 (2002), 473–480.
150. [150] Watnasirichaikul, S., Rades, T., Tucker, I.G., Davies, N.M., Effects of formulation variables on characteristics of poly (ethylcyanoacrylate) nanocapsules prepared from w/o microemulsions. Int. J. Pharm. 235:1–2 (2002), 237–246.
151. [151] Watnasirichaikul, S., Davies, N., Rades, T., Tucker, I., Preparation of biodegradable insulin nanocapsules from biocompatible microemulsions. Pharm. Res. 17:6 (2000), 684–689.
152. [152] Graf, A., Rades, T., Hook, S.M., Oral insulin delivery using nanoparticles based on microemulsions with different structure-types: optimisation and in vivo evaluation. Eur. J. Pharm. Sci. 37:1 (2009), 53–61.
153. [153] Michel, C., Aprahamian, M., Defontaine, L., Couvreur, P., DamgÉ, C., The effect of site of administration in the gastrointestinal tract on the absorption of insulin from nanocapsules in diabetic rats. J. Pharm. Pharmacol. 43:1 (1991), 1–5.
154. [154] Damgé, C., Michel, C., Aprahamian, M., Couvreur, P., Devissaguet, J.P., Nanocapsules as carriers for oral peptide delivery. J. Control. Release 13:2–3 (1990), 233–239.
155. [155] Cournarie, F., Auchere, D., Chevenne, D., Lacour, B., Seiller, M., Vauthier, C., Absorption and efficiency of insulin after oral administration of insulin-loaded nanocapsules in diabetic rats. Int. J. Pharm. 242:1–2 (2002), 325–328.
156. [156] Pinto-Alphandary, H., Aboubakar, M., Jaillard, D., Couvreur, P., Vauthier, C., Visualization of insulin-loaded nanocapsules: in vitro and in vivo studies after oral administration to rats. Pharm. Res. 20:7 (2003), 1071–1084.
157. [157] Graf, A., Jack, K.S., Whittaker, A.K., Hook, S.M., Rades, T., Protein delivery using nanoparticles based on microemulsions with different structure-types. Eur. J. Pharm. Sci. 33:4-5 (2008), 434–444.
158. [158] Lowe, P.J., Temple, C.S., Calcitonin and insulin in isobutylcyanoacrylate nanocapsules: protection against proteases and effect on intestinal absorption in rats. J. Pharm. Pharmacol. 46:7 (1994), 547–552.
159. [159] Sai, P., Damgé, C., Rivereau, A.S., et al. Prophylactic oral administration of metabolically active insulin entrapped in isobutylcyanoacrylate nanocapsules reduces the incidence of diabetes in non obese diabetic mice. J. Autoimmun. 9:6 (1996), 713–721.
160. [160] Krauel, K., Davies, N.M., Hook, S., Rades, T., Using different structure types of microemulsions for the preparation of poly(alkylcyanoacrylate) nanoparticles by interfacial polymerization. J. Control. Release 106:1-2 (2005), 76–87.
161. [161] Kafka, A.P., McLeod, B.J., Rades, T., McDowell, A., Release and bioactivity of PACA nanoparticles containing D-Lys(6)-GnRH for brushtail possum fertility control. J. Control. Release 149:3 (2011), 307–313.
162. [162] Elizondo, E., Moreno, E., Cabrera, I., Cordoba, A., Sala, S., Veciana, J., et al. Liposomes and other vesicular systems: structural characteristics, methods of preparation, and use in nanomedicine. Prog. Mol. Biol. Transl. Sci. 104 (2011), 1–52.
163. [163] Swaminathan, J., Ehrhardt, C., Liposomal delivery of proteins and peptides. Expert Opin. Drug Deliv. 9:12 (2012), 1489–1503.
164. [164] Bangham, A.D., Standish, M.M., Watkins, J.C., Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 13:1 (1965), 238–252.
165. [165] Bangham, A.D., Horne, R.W., Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J. Mol. Biol. 8 (1964), 660–668.
166. [166] Madni, A., Sarfraz, M., Rehman, M., Ahmad, M., Akhtar, N., Ahmad, S., et al. Liposomal drug delivery: a versatile platform for challenging clinical applications. J. Pharm. Pharm. Sci. 17:3 (2014), 401–426.
167. [167] Carafa, M., Marianecci, C., Annibaldi, V., Di Stefano, A., Sozio, P., Santucci, E., Novel O-palmitoylscleroglucan-coated liposomes as drug carriers: development, characterization and interaction with leuprolide. Int. J. Pharm. 325:1-2 (2006), 155–162.
168. [168] Agrawal, A.K., Harde, H., Thanki, K., Jain, S., Improved stability and antidiabetic potential of insulin containing folic acid functionalized polymer stabilized multilayered liposomes following oral administration. Biomacromolecules 15:1 (2014), 350–360.
169. [169] Mohanraj, V.J., Barnes, T.J., Prestidge, C.A., Silica nanoparticle coated liposomes: a new type of hybrid nanocapsule for proteins. Int. J. Pharm. 392:1-2 (2010), 285–293.
170. [170] Li, Z., Chen, J., Sun, W., Xu, Y., Investigation of archaeosomes as carriers for oral delivery of peptides. Biochem. Biophys. Res. Commun. 394:2 (2010), 412–417.
171. [171] Pardakhty, A., Varshosaz, J., Rouholamini, A., In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin. Int. J. Pharm. 328:2 (2007), 130–141.
172. [172] Iwanaga, K., Ono, S., Narioka, K., Kakemi, M., Morimoto, K., Yamashita, S., et al. Application of surface-coated liposomes for oral delivery of peptide: effects of coating the liposome's surface on the GI transit of insulin. J. Pharm. Sci. 88:2 (1999), 248–252.
173. [173] Choudhari, K.B., Labhasetwar, V., Dorle, A.K., Liposomes as a carrier for oral administration of insulin: effect of formulation factors. J. Microencapsul. 11:3 (1994), 319–325.
174. [174] Carvalho, E.L.S., Grenha, A., Remuñán-López, C., Alonso, M.J., Seijo, B., Mucosal delivery of liposome–chitosan nanoparticle complexes. Methods in Enzymology, vol. 465, 2009, Academic Press, 289–312.
175. [175] Kisel, M.A., Kulik, L.N., Tsybovsky, I.S., Vlasov, A.P., Vorob'yov, M.S., Kholodova, E.A., et al. Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: studies in the rat. Int. J. Pharm. 216:1–2 (2001), 105–114.
176. [176] Makhlof, A., Fujimoto, S., Tozuka, Y., Takeuchi, H., In vitro and in vivo evaluation of WGA-carbopol modified liposomes as carriers for oral peptide delivery. Eur. J. Pharm. Biopharm. 77:2 (2011), 216–224.
177. [177] Thirawong, N., Thongborisute, J., Takeuchi, H., Sriamornsak, P., Improved intestinal absorption of calcitonin by mucoadhesive delivery of novel pectin-liposome nanocomplexes. J. Control. Release 125:3 (2008), 236–245.
178. [178] Thongborisute, J., Tsuruta, A., Kawabata, Y., Takeuchi, H., The effect of particle structure of chitosan-coated liposomes and type of chitosan on oral delivery of calcitonin. J. Drug Target. 14:3 (2006), 147–154.
179. [179] Takeuchi, H., Matsui, Y., Sugihara, H., Yamamoto, H., Kawashima, Y., Effectiveness of submicron-sized, chitosan-coated liposomes in oral administration of peptide drugs. Int. J. Pharm. 303:1-2 (2005), 160–170.
180. [180] Takeuchi, H., Matsui, Y., Yamamoto, H., Kawashima, Y., Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats. J. Control. Release 86:2–3 (2003), 235–242.
181. [181] Chen, D., Xia, D., Li, X., Zhu, Q., Yu, H., Zhu, C., et al. Comparative study of pluronic F127-modified liposomes and chitosan-modified liposomes for mucus penetration and oral absorption of cyclosporine A in rats. Int. J. Pharm. 449:1-2 (2013), 1–9.
182. [182] Kowapradit, J., Apirakaramwong, A., Ngawhirunpat, T., Rojanarata, T., Sajomsang, W., Opanasopit, P., Methylated N-(4-N,N-dimethylaminobenzyl) chitosan coated liposomes for oral protein drug delivery. Eur. J. Pharm. Sci. 47:2 (2012), 359–366.
183. [183] Parmentier, J., Thewes, B., Gropp, F., Fricker, G., Oral peptide delivery by tetraether lipid liposomes. Int. J. Pharm. 415:1-2 (2011), 150–157.
184. [184] Zhang, X., Qi, J., Lu, Y., He, W., Li, X., Wu, W., Biotinylated liposomes as potential carriers for the oral delivery of insulin. Nanomedicine 10:1 (2014), 167–176.
185. [185] Zhang, X., Qi, J., Lu, Y., Hu, X., He, W., Wu, W., Enhanced hypoglycemic effect of biotin-modified liposomes loading insulin: effect of formulation variables, intracellular trafficking, and cytotoxicity. Nanoscale Res. Lett., 9(1), 2014, 185.
186. [186] Niu, M., Lu, Y., Hovgaard, L., Guan, P., Tan, Y., Lian, R., et al. Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose. Eur. J. Pharm. Biopharm. 81:2 (2012), 265–272.
187. [187] Niu, M., Tan, Y., Guan, P., Hovgaard, L., Lu, Y., Qi, J., et al. Enhanced oral absorption of insulin-loaded liposomes containing bile salts: a mechanistic study. Int. J. Pharm. 460:1-2 (2014), 119–130.
188. [188] Hu, S., Niu, M., Hu, F., Lu, Y., Qi, J., Yin, Z., et al. Integrity and stability of oral liposomes containing bile salts studied in simulated and ex vivo gastrointestinal media. Int. J. Pharm. 441:1-2 (2013), 693–700.
189. [189] Moghassemi, S., Parnian, E., Hakamivala, A., Darzianiazizi, M., Vardanjani, M.M., Kashanian, S., et al. Uptake and transport of insulin across intestinal membrane model using trimethyl chitosan coated insulin niosomes. Mater. Sci. Eng., C 46 (2015), 333–340.
190. [190] Zhang, N., Ping, Q.N., Huang, G.H., Xu, W.F., Investigation of lectin-modified insulin liposomes as carriers for oral administration. Int. J. Pharm. 294:1-2 (2005), 247–259.
191. [191] Li, H., An, J., Park, J.-S., Han, K., Multivesicular liposomes for oral delivery of recombinant human epidermal growth factor. Arch. Pharm. Res. 28:8 (2005), 988–994.
192. [192] Frkanec, R., Noethig-Laslo, V., Vranešić, B., Mirosavljević, K., Tomašić, J., A spin labelling study of immunomodulating peptidoglycan monomer and adamantyltripeptides entrapped into liposomes. Biochim. Biophys. Acta Biomembr. 1611:1-2 (2003), 187–196.
193. [193] Ibraheem, D., Elaissari, A., Fessi, H., Administration strategies for proteins and peptides. Int. J. Pharm. 477:1-2 (2014), 578–589.
194. [194] Anderson, M., Omri, A., The effect of different lipid components on the in vitro stability and release kinetics of liposome formulations. Drug Deliv. 11:1 (2004), 33–39.
195. [195] Grenha, A., Remuñán-López, C., Carvalho, E.L.S., Seijo, B., Microspheres containing lipid/chitosan nanoparticles complexes for pulmonary delivery of therapeutic proteins. Eur. J. Pharm. Biopharm. 69:1 (2008), 83–93.
196. [196] Katayama, K., Kato, Y., Onishi, H., Nagai, T., Machida, Y., Double liposomes: hypoglycemic effects of liposomal insulin on normal rats. Drug Dev. Ind. Pharm. 29:7 (2003), 725–731.
197. [197] Goto, T., Morishita, M., Nishimura, K., Nakanishi, M., Kato, A., Ehara, J., et al. Novel mucosal insulin delivery systems based on fusogenic liposomes. Pharm. Res. 23:2 (2006), 384–391.
198. [198] Gradauer, K., Barthelmes, J., Vonach, C., Almer, G., Mangge, H., Teubl, B., et al. Liposomes coated with thiolated chitosan enhance oral peptide delivery to rats. J. Control. Release 172:3 (2013), 872–878.
199. [199] Gradauer, K., Dünnhaupt, S., Vonach, C., Szöllösi, H., Pali-Schöll, I., Mangge, H., et al. Thiomer-coated liposomes harbor permeation enhancing and efflux pump inhibitory properties. J. Control. Release 165:3 (2013), 207–215.
200. [200] Yamabe, K., Kato, Y., Onishi, H., Machida, Y., Potentiality of double liposomes containing salmon calcitonin as an oral dosage form. J. Control. Release 89:3 (2003), 429–436.
201. [201] Cheng, W., Lim, L.-Y., Comparison of reversible and nonreversible aqueous-soluble lipidized conjugates of salmon calcitonin. Mol. Pharm. 5:4 (2008), 610–621.
202. [202] Uchiyama, T., Kotani, A., Tatsumi, H., Kishida, T., Okamoto, A., Okada, N., et al. Development of novel lipophilic derivatives of dadle (leucine enkephalin analogue): intestinal permeability characteristics of DADLE derivatives in rats. Pharm. Res. 17:12 (2000), 1461–1467.
203. [203] Delie, F., Couvreur, P., Nisato, D., Michel, J.-B., Puisieux, F., Letourneux, Y., Synthesis and in vitro study of a diglyceride prodrug of a peptide. Pharm. Res. 11:8 (1994), 1082–1087.
204. [204] Fujita, T., Kawahara, I., Quan, Y., Hattori, K., Takenaka, K., Muranishi, S., et al. Permeability characteristics of tetragastrins across intestinal membranes using the Caco-2 monolayer system: comparison between acylation and application of protease inhibitors. Pharm. Res. 15:9 (1998), 1387–1392.
205. [205] Fujita, T., Fujita, T., Morikawa, K., Tanaka, H., Iemura, O., Yamamoto, A., et al. Improvement of intestinal absorption of human calcitonin by chemical modification with fatty acids: synergistic effects of acylation and absorption enhancers. Int. J. Pharm. 134:1–2 (1996), 47–57.
206. [206] Wang, J., Chow, D., Heiati, H., Shen, W.-C., Reversible lipidization for the oral delivery of salmon calcitonin. J. Control. Release 88:3 (2003), 369–380.
207. [207] Lalatsa, A., Lee, V., Malkinson, J.P., Zloh, M., Schatzlein, A.G., Uchegbu, I.F., A prodrug nanoparticle approach for the oral delivery of a hydrophilic peptide, leucine(5)-enkephalin, to the brain. Mol. Pharm. 9:6 (2012), 1665–1680.
208. [208] Teijeiro, C., McGlone, A., Csaba, N., Garcia-Fuentes, M., MJ, A., Polysaccharide-based nanocarriers for drug delivery. Handbook of Nanobiomedical Research, 2014, 235–277.
209. [209] Norris, D.A., Puri, N., Sinko, P.J., The effect of physical barriers and properties on the oral absorption of particulates. Adv. Drug Deliv. Rev. 34:2–3 (1998), 135–154.
210. [210] Lai, S.K., O'Hanlon, D.E., Harrold, S., Man, S.T., Wang, Y.Y., Cone, R., et al. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc. Natl. Acad. Sci. U. S. A. 104:5 (2007), 1482–1487.
211. [211] Dünnhaupt, S., Kammona, O., Waldner, C., Kiparissides, C., Bernkop-Schnürch, A., Nano-carrier systems: strategies to overcome the mucus gel barrier. Eur. J. Pharm. Biopharm. 96 (2015), 447–453.
212. [212] Friedl, H., Dünnhaupt, S., Hintzen, F., Waldner, C., Parikh, S., Pearson, J.P., Development and evaluation of a novel mucus diffusion test system approved by self-nanoemulsifying drug delivery systems. J. Pharm. Sci. 102:12 (2013), 4406–4413.
213. [213] Tobio, M., Sanchez, A., Vila, A., Soriano, I.I., Evora, C., Vila-Jato, J.L., Alonso, M.J., The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloids Surf. B: Biointerfaces 18 (2000), 315–323.
214. [214] Ensign, L.M., Tang, B.C., Wang, Y.Y., Tse, T.A., Hoen, T., Cone, R., et al. Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci. Transl. Med., 4(138), 2012, 138ra79.
215. [215] Ensign, L.M., Cone, R., Hanes, J., Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv. Drug Deliv. Rev. 64:6 (2012), 557–570.
216. [216] Maisel, K., Ensign, L., Reddy, M., Cone, R., Hanes, J., Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse. J. Control. Release 197 (2015), 48–57.
217. [217] Li, X., Chen, D., Le, C., Zhu, C., Gan, Y., Hovgaard, L., et al. Novel mucus-penetrating liposomes as a potential oral drug delivery system: preparation, in vitro characterization, and enhanced cellular uptake. Int. J. Nanomedicine 6 (2011), 3151–3162.
218. [218] Groo, A.-C., Saulnier, P., Gimel, J.-C., Gravier, J., Ailhas, C., Benoit, J.-P., et al. Fate of paclitaxel lipid nanocapsules in intestinal mucus in view of their oral delivery. Int. J. Nanomedicine 8 (2013), 4291–4302.
219. [219] Groo, A.-C., Lagarce, F., Mucus models to evaluate nanomedicines for diffusion. Drug Discov. Today 19:8 (2014), 1097–1108.
220. [220] Mehnert, W., Mäder, K., Solid lipid nanoparticles production, characterization and applications. Adv. Drug Deliv. Rev. 64 (2012), 83–101.
221. [221] Lyons, K.C., Charman, W.N., Miller, R., Porter, C.J., Factors limiting the oral bioavailability of N-acetylglucosaminyl-N-acetylmuramyl dipeptide (GMDP) and enhancement of absorption in rats by delivery in a water-in-oil microemulsion. Int. J. Pharm. 199:1 (2000), 17–28.
222. [222] Brayden, D.J., Gleeson, J., Walsh, E.G., A head-to-head multi-parametric high content analysis of a series of medium chain fatty acid intestinal permeation enhancers in Caco-2 cells. Eur. J. Pharm. Biopharm. 88:3 (2014), 830–839.
223. [223] Brayden, D.J., Walsh, E., Efficacious intestinal permeation enhancement induced by the sodium salt of 10-undecylenic acid, a medium chain fatty acid derivative. AAPS J. 16:5 (2014), 1064–1076.
224. [224] Anderson, W.B., Jaworski, C.J., Modulation of adenylate cyclase activity of fibroblasts by free fatty acids and phospholipids. Arch. Biochem. Biophys. 180:2 (1977), 374–383.
225. [225] Francoeur, M.L., Golden, G.M., Potts, R.O., Oleic acid: its effects on stratum corneum in relation to (trans)dermal drug delivery. Pharm. Res. 7:6 (1990), 621–627.
226. [226] Stillwell, W., Ehringer, W., Jenski, L., Docosahexaenoic acid increases permeability of lipid vesicles and tumor cells. Lipids 28:2 (1993), 103–108.
227. [227] Luo, Y., Teng, Z., Li, Y., Wang, Q., Solid lipid nanoparticles for oral drug delivery: chitosan coating improves stability, controlled delivery, mucoadhesion and cellular uptake. Carbohydr. Polym. 122 (2015), 221–229.
228. [228] Damgé, C., Aprahamian, M., Humbert, W., Pinget, M., Ileal uptake of polyalkylcyanoacrylate nanocapsules in the rat. J. Pharm. Pharmacol. 52:9 (2000), 1049–1056.
229. [229] Ilan, E., Amselem, S., Weisspapir, M., Schwarz, J., Yogev, A., Zawoznik, E., et al. Improved oral delivery of desmopressin via a novel vehicle: mucoadhesive submicron emulsion. Pharm. Res. 13:7 (1996), 1083–1087.
230. [230] Grenha, A., Seijo, B., Serra, C., Remunan-Lopez, C., Surface characterization of lipid/chitosan nanoparticles assemblies, using X-ray photoelectron spectroscopy and time-of-flight secondary ion mass spectrometry. J. Nanosci. Nanotechnol. 8:1 (2008), 358–365.
231. [231] Guo, L., Ma, E., Zhao, H., Long, Y., Zheng, C., Duan, M., Preliminary evaluation of a novel oral delivery system for rhPTH1-34: in vitro and in vivo. Int. J. Pharm. 420:1 (2011), 172–179.
232. [232] Hintzen, F., Perera, G., Hauptstein, S., Muller, C., Laffleur, F., Bernkop-Schnurch, A., In vivo evaluation of an oral self-microemulsifying drug delivery system (SMEDDS) for leuprorelin. Int. J. Pharm. 472:1-2 (2014), 20–26.
233. [233] Patel, M., Shah, T., Amin, A., Therapeutic opportunities in colon-specific drug-delivery systems. Crit. Rev. Ther. Drug Carrier Syst. 24:2 (2007), 147–202.
234. [234] Beskid, G., Unowsky, J., Behl, C.R., Siebelist, J., Tossounian, J.L., McGarry, C.M., et al. Enteral, oral, and rectal absorption of ceftriaxone using glyceride enhancers. Chemotherapy 34:2 (1988), 77–84.
235. [235] Yeh, P.Y., Smith, P.L., Ellens, H., Effect of medium-chain glycerides on physiological properties of rabbit intestinal epithelium in vitro. Pharm. Res. 11:8 (1994), 1148–1154.
236. [236] Maroni, A., Zema, L., Del Curto, M.D., Foppoli, A., Gazzaniga, A., Oral colon delivery of insulin with the aid of functional adjuvants. Adv. Drug Deliv. Rev. 64:6 (2012), 540–556.
237. [237] Patel, M.M., Colon targeting: an emerging frontier for oral insulin delivery. Expert Opin. Drug Deliv. 10:6 (2013), 731–739.
238. [238] Tozaki, H., Komoike, J., Tada, C., Maruyama, T., Terabe, A., Suzuki, T., et al. Chitosan capsules for colon-specific drug delivery: improvement of insulin absorption from the rat colon. J. Pharm. Sci. 86:9 (1997), 1016–1021.
239. [239] Jindal, S.K., Singh, M., Goswami, M., Formulation and evaluation of insulin enteric microspheres for oral drug delivery. Acta Pharm. Sci. 51 (2009), 121–127.
240. [240] Katsuma, M., Watanabe, S., Kawai, H., Takemura, S., Sako, K., Effects of absorption promoters on insulin absorption through colon-targeted delivery. Int. J. Pharm. 307:2 (2006), 156–162.
241. [241] Fetih, G., Fausia, H., Okada, N., Fujita, T., Attia, M., Yamamoto, A., Colon-specific delivery and enhanced colonic absorption of [Asu(1,7)]-eel calcitonin using chitosan capsules containing various additives in rats. J. Drug Target. 14:3 (2006), 165–172.
242. [242] Aguirre, T.A.S., Rosa, M., Coulter, I., Brayden, D.J.,. In vitro and in vivo preclinical evaluation of a minisphere emulsion-based formulation (SmPill®) of salmon calcitonin. Eur. J. Pharm. Sci. 79 (2015), 102–111.
243. [243] Keohane, K., Rosa, M., Coulter, I.S., Griffin, B.T., Enhanced colonic delivery of ciclosporin A self-emulsifying drug delivery system encapsulated in coated minispheres. Drug Dev. Ind. Pharm., 1-9, 2015.
244. [244] Venkatesan, N., Yoshimitsu, J., Ito, Y., Shibata, N., Takada, K., Liquid filled nanoparticles as a drug delivery tool for protein therapeutics. Biomaterials 26:34 (2005), 7154–7163.
245. [245] Leonard, T.W., Lynch, J., McKenna, M.J., Brayden, D.J., Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPET. Expert Opin. Drug Deliv. 3:5 (2006), 685–692.